PT690863E - Compostos tetraciclicos como agonistas da dopamina - Google Patents

Compostos tetraciclicos como agonistas da dopamina

Info

Publication number
PT690863E
PT690863E PT94912799T PT94912799T PT690863E PT 690863 E PT690863 E PT 690863E PT 94912799 T PT94912799 T PT 94912799T PT 94912799 T PT94912799 T PT 94912799T PT 690863 E PT690863 E PT 690863E
Authority
PT
Portugal
Prior art keywords
compounds
image
tetraciclic
dopamine agonists
treatment
Prior art date
Application number
PT94912799T
Other languages
English (en)
Inventor
Michael R Michaelides
Yufeng Hong
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of PT690863E publication Critical patent/PT690863E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PT94912799T 1993-04-06 1994-03-18 Compostos tetraciclicos como agonistas da dopamina PT690863E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4342493A 1993-04-06 1993-04-06
US20998294A 1994-03-17 1994-03-17

Publications (1)

Publication Number Publication Date
PT690863E true PT690863E (pt) 2003-07-31

Family

ID=26720416

Family Applications (1)

Application Number Title Priority Date Filing Date
PT94912799T PT690863E (pt) 1993-04-06 1994-03-18 Compostos tetraciclicos como agonistas da dopamina

Country Status (15)

Country Link
US (1) US5597832A (pt)
EP (1) EP0690863B1 (pt)
JP (1) JP2710695B2 (pt)
KR (1) KR100383342B1 (pt)
CN (1) CN1046723C (pt)
AT (1) ATE233765T1 (pt)
AU (1) AU677842B2 (pt)
BR (1) BR9405972A (pt)
DE (1) DE69432217T2 (pt)
DK (1) DK0690863T3 (pt)
ES (1) ES2193158T3 (pt)
FI (1) FI954738A7 (pt)
NO (1) NO311762B1 (pt)
PT (1) PT690863E (pt)
WO (1) WO1994022858A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5659037A (en) * 1994-08-18 1997-08-19 Abbott Laboratories Process for preparing chiral tetracyclic dopaminergic compounds
JP3036847B2 (ja) 1995-01-13 2000-04-24 サマーセット・ファーマシューティカルズ・インコーポレイテッド デスメチルセレギリンを用いる方法および医薬組成物
WO1996025411A1 (en) 1995-02-15 1996-08-22 Neurogen Corporation Certain bridged 4-phenyl-2-aminomethylimidazoles; new dopamine receptor subtype specific ligands
US5668141A (en) * 1996-04-02 1997-09-16 Abbott Laboratories Trans-2,6-,3,6-and 4,6-diaza-5,6,6a,7,8,12b-hexahydrobenzo[c]phenanthrene compounds as dopamine agonists
DE19644228A1 (de) * 1996-10-24 1998-04-30 Merck Patent Gmbh Thienopyrimidine
EP1006794B1 (en) * 1997-03-12 2007-11-28 Robert W. Esmond A method for treating or preventing alzheimer's disease
US6193954B1 (en) 1997-03-21 2001-02-27 Abbott Laboratories Formulations for pulmonary delivery of dopamine agonists
AU750808B2 (en) 1997-10-03 2002-07-25 Cary Medical Corporation Compositon for the treatment of nicotine addiction containing a nicotine receptor antagonist and an anti-depressant or anti-anxiety drug
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
GB9828861D0 (en) * 1998-12-31 1999-02-17 Danbiosyst Uk Compositions
US6147226A (en) * 1999-02-16 2000-11-14 Great Lakes Chemical Corporation Synthesis of cyclopentyl 2-thienyl ketone, tiletamine and tiletamine acid addition salts, such as tiletamine hydrochloride
US5969159A (en) * 1999-02-16 1999-10-19 Great Lakes Chemical Corporation Synthesis of cyclopentyl 2-thienyl ketone tiletamine and tiletamine acid addition salts such as tiletamine hydrochloride
US6638929B2 (en) * 1999-12-29 2003-10-28 Wyeth Tricyclic protein kinase inhibitors
PL363365A1 (en) * 2000-08-16 2004-11-15 Pharmacia & Upjohn Company Compounds for the treatment of addictive disorders
US20070243240A9 (en) * 2000-08-24 2007-10-18 Fred Windt-Hanke Transdermal therapeutic system
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE60323339D1 (de) 2002-02-15 2008-10-16 Darpharma Inc Monoester und asymmetrisch substituierte diester prodrugs der dopamin-d1-rezeptor-agonisten
US20100168085A1 (en) * 2003-05-22 2010-07-01 Yesa Research And Development Co. Ltd. At The Weizmann Institute Of Science Dopamine and agonists and antagonists thereof for modulation of suppressive activity of CD4+CD25+ regulatory T cells
WO2005055920A2 (en) * 2003-12-09 2005-06-23 Yeda Research And Development Co. Ltd. Compositions and methods for treatment of psychiatric disorders
EP1699450A4 (en) * 2003-12-23 2009-11-11 Darpharma Inc Simultaneous administration of dopamine receptor bindings
NZ570606A (en) * 2006-02-21 2011-11-25 Purdue Research Foundation Trans-fused chromenoisoquinolines, synthesis and methods for use
WO2010124005A1 (en) 2009-04-21 2010-10-28 Purdue Research Foundation Octahydrobenzoisoquinoline modulators of dopamine receptors and uses therefor
WO2013134047A2 (en) 2012-03-07 2013-09-12 The Mclean Hospital Corporation Aminoquinoline derivatives and uses thereof
CN103387583B (zh) * 2012-05-09 2018-04-13 中国科学院上海药物研究所 二芳基并[a,g]喹嗪类化合物、其制备方法、药物组合物及其应用
RU2537170C1 (ru) * 2013-11-20 2014-12-27 Войсковая Часть 41598 Средство профилактики церебральной формы острой лучевой болезни

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2691024A (en) * 1952-05-26 1954-10-05 Schenley Ind Inc Dihydropyrrolo-(3.2-c) quinoline derivatives
US3541100A (en) * 1967-12-14 1970-11-17 American Cyanamid Co Benzheteroazolo(2,3-a)isoquinolium salts
GB1379387A (en) * 1970-12-11 1975-01-02 Agfa Gevaert Photoconductive recording materials
US3943137A (en) * 1973-07-09 1976-03-09 University Of Kansas Endowment Association Acronycine derivatives
NL7605526A (nl) * 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
US4340600A (en) * 1980-05-22 1982-07-20 Smithkline Corporation Renal dilating methods and compositions using 4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinolines
US4282227A (en) * 1980-05-22 1981-08-04 Smithkline Corporation Renal vasodilating 3,4-dihydroxyphenyltetrahydrothienopyridines
US5047536A (en) * 1989-03-17 1991-09-10 Purdue Research Foundation Hexahydrobenzo(A)phenanthridine compounds
WO1993024462A1 (en) * 1992-05-26 1993-12-09 Purdue Research Foundation Substituted-hexahydrobenzo[a]phenanthridines

Also Published As

Publication number Publication date
JP2710695B2 (ja) 1998-02-10
CN1124489A (zh) 1996-06-12
FI954738L (fi) 1995-12-05
BR9405972A (pt) 1995-12-12
FI954738A0 (fi) 1995-10-05
EP0690863B1 (en) 2003-03-05
JPH08508487A (ja) 1996-09-10
KR100383342B1 (ko) 2003-08-25
US5597832A (en) 1997-01-28
DE69432217T2 (de) 2004-04-08
NO311762B1 (no) 2002-01-21
DK0690863T3 (da) 2003-06-30
DE69432217D1 (de) 2003-04-10
ATE233765T1 (de) 2003-03-15
FI954738A7 (fi) 1995-12-05
CN1046723C (zh) 1999-11-24
ES2193158T3 (es) 2003-11-01
WO1994022858A1 (en) 1994-10-13
NO953957L (no) 1995-11-21
NO953957D0 (no) 1995-10-05
AU677842B2 (en) 1997-05-08
AU6520394A (en) 1994-10-24
EP0690863A1 (en) 1996-01-10
EP0690863A4 (en) 1995-11-07
KR960701870A (ko) 1996-03-28

Similar Documents

Publication Publication Date Title
PT690863E (pt) Compostos tetraciclicos como agonistas da dopamina
GEP20022676B (en) 4-Phenyl-Pyridine Derivatives, Method for Their Production and Their Use for Treatment of Disorders Caused by Antagonist of NK-1 Receptors
ID22636A (id) Zat-zat terapeutik
TR200100659T2 (tr) 5-HT2C agonistleri olarak piroloindoller, piridoindoller ve azepinoindoller.
ES2071334T3 (es) Analogos de anillos fusionados de nitrogeno conteniendo heterociclos no aromaticos.
UY27026A1 (es) Derivados benzodiacepínicos como moduladores de los receptores gaba a
BR0311771A (pt) Derivados de nonano e azabiciclo-octano com atividade inibitória da ddp-iv
YU40300A (sh) Aril fuzirana azapoliciklična jedinjenja
CA2286723A1 (en) Tricyclic compounds
MX9304996A (es) Heterociclos no-aromaticos que contienen bencilamino nitrogeno substituido.
MA27119A1 (fr) Modulateurs tetrahydropyranyle cyclopentyle tetrahydropyrido pyridine de l'activite d'un recepteur de chimiokine
CA2239705A1 (en) Quinazoline-4-one ampa antagonists
EP1189900A4 (en) HETEROCYCLIC AMINOPYRROLIDINE DERIVATIVES FOR USE AS MELATONERGIC AGENTS
NZ316312A (en) Novel fused isoquinolines as dopamine receptor ligands
ES2173182T3 (es) Derivado de 4,6-dl-butil-2,3-dihidrobenzotiofenos como antioxidantes de ldl.
DK0688320T3 (da) Heterocycliske forbindelser, anvendelse og fremstilling deraf
MY111699A (en) Isoquinoline derivatives as therapeutic agents
GB9907055D0 (en) Antibacterial agents
CA2159481A1 (en) Tetracyclic compounds as dopamine agonists
WO2002024641A1 (en) Tricyclic indole compounds having affinity for serotonin receptor
ES2087813A1 (es) Heterociclos no-aromaticos que contienen nitrogeno bencilamino substituidos.
PE20080172A1 (es) Compuestos dihidrobenzofuranil alcanamida como moduladores del receptor 5-ht2c
MX9706245A (es) Ciertos 4-fenil-2-aminometilimidazoles con puentes quimicos, nuevos ligandos especificos del subtipodel receptor de dopamina.
NZ503588A (en) 2,3,3a,7b-tetrahydro-1H-benzo[3,4]cyclobuta[1,2-c]pyrrole derivatives useful as serotonin reuptake inhibitors
TH125052A (th) อนุพันธ์ไตรไซคลิกอินดีโน-พรัยโรลเป็นสารปรับตัวรับเซอโรโทนิน